HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited

Hutchmed (China) Limited ($HCM) announced an update on their ongoing clinical study. Hutchmed has launched a new early stage trial for HMPL-A251 in...

Hutchmed’s New HER2 Trial Adds Early Stage Upside to Its Oncology Pipeline

In a report released on May 21, from UBS maintained a Buy rating on HUTCHMED (China) , with a price target of HK$34.10. The company’s shares closed...

UBS Reaffirms Their Buy Rating on HUTCHMED (China)  (HCM)

Bernstein analyst Pujarini Ghosh maintained a Buy rating on Holcim yesterday. The company’s shares closed last Wednesday at CHF72.38. According to ...

Bernstein Keeps Their Buy Rating on Holcim (0QKY)

HUTCHMED (China) ( ($HK:0013) ) has issued an announcement. HUTCHMED (China) Limited reported that all ordinary and special resolutions proposed at...

HUTCHMED shareholders approve all resolutions at 2026 AGM

In a report released yesterday, Elodie Rall from J.P. Morgan maintained a Buy rating on Holcim. The company’s shares closed last Friday at CHF75.22...

J.P. Morgan Remains a Buy on Holcim (0QKY)

Erste Group analyst Hans Engel maintained a Hold rating on Holcim yesterday. The company’s shares closed yesterday at CHF70.76. According to TipRan...

Erste Group Sticks to Its Hold Rating for Holcim (0QKY)

UBS analyst Julian Radlinger maintained a Buy rating on Holcim today and set a price target of CHF93.00. According to TipRanks, Radlinger is a 2-st...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HCM	$11.23	-4.18%	61.98K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HCM	$11.23	-4.2%	61.98K
3
4
5
6

HCM

HCM

Dividend Overview

Get HUTCHMED (China) Limited Data in Excel

Get HUTCHMED (China) Limited Data in Excel